NanoString Technologies (NASDAQ:NSTG) and Passage Bio (NASDAQ:PASG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.
Institutional and Insider Ownership
98.3% of NanoString Technologies shares are held by institutional investors. Comparatively, 67.6% of Passage Bio shares are held by institutional investors. 4.2% of NanoString Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and recommmendations for NanoString Technologies and Passage Bio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
NanoString Technologies | 0 | 1 | 5 | 0 | 2.83 |
Passage Bio | 0 | 2 | 6 | 0 | 2.75 |
NanoString Technologies currently has a consensus target price of $63.00, indicating a potential upside of 3.26%. Passage Bio has a consensus target price of $25.5297, indicating a potential upside of 31.39%. Given Passage Bio's higher probable upside, analysts plainly believe Passage Bio is more favorable than NanoString Technologies.
Valuation & Earnings
This table compares NanoString Technologies and Passage Bio's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
NanoString Technologies | $125.57 million | 21.41 | $-40,700,000.00 | ($1.93) | -31.61 |
Passage Bio | N/A | N/A | N/A | N/A | N/A |
Passage Bio has lower revenue, but higher earnings than NanoString Technologies.
Profitability
This table compares NanoString Technologies and Passage Bio's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
NanoString Technologies | -53.47% | -68.96% | -24.15% |
Passage Bio | N/A | N/A | N/A |
Summary
Passage Bio beats NanoString Technologies on 5 of the 9 factors compared between the two stocks.